Kyverna Therapeutics Inc., a clinical-stage biopharmaceutical company, will host a virtual KOL event on August 28, 2025, to discuss its neuroimmunology franchise. The event will focus on Kyverna's strategy, particularly on KYV-101 and its potential in treating myasthenia gravis and stiff person syndrome. Presentations will cover the treatment landscape, patient experiences, unmet needs, and details of the Phase 3 registrational trial in myasthenia gravis. The event will be webcast live, with a Q&A session following the formal presentations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.